Aurinia Pharmaceuticals Inc expected to post a loss of 2 cents a share - Earnings Preview

Aurinia Pharmaceuticals

25/02/2025 13:49

Aurinia Pharmaceuticals Inc AUPH.OQ AUPH.O is expected to show a rise in quarterly revenue when it reports  results on February 27 for the period ending December 31 2024

The Edmonton Alberta-based  company is expected to report a 33.3% increase in revenue to $60.111 million from $45.1 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aurinia Pharmaceuticals Inc is for a loss of 2 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $10.93​, above​ its last closing price of $8.05. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
0.02
0.02
0.10
Beat
566.7
Jun. 30 2024
0.01
0.01
0.01
Met
20
Mar. 31 2024
-0.18
-0.14
-0.03
Beat
78​
Dec. 31 2023
-0.16
-0.16
-0.19
Missed
-16.3
​​Sep. 30 2023
-0.16
-0.17
-0.09
Beat
46.2
Jun. 30 2023
-0.18
-0.18
-0.08
Beat
56.4​
Mar. 31 2023
-0.22
-0.22
-0.18
Beat
18.7
Dec. 31 2022
-0.27
-0.27
-0.18
Beat
34

This summary was machine generated February 25 at 13:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)